12:48 PM EDT, 08/27/2024 (MT Newswires) -- Nuvectis Pharma's ( NVCT ) NXP800 has received orphan drug designation from the US Food and Drug Administration, according to the FDA website Tuesday.

The orphan designation is for the treatment of AT-rich interactive domain-containing protein 1a-deficient ovarian cancer, fallopian tube cancer, and primary peritoneal cancer, the website showed.

Shares of the company were up about 1.9% in recent trading.

Price: 7.07, Change: +0.13, Percent Change: +1.92